Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Kang

Vascular Surgery Canton, GA Medical Doctor

NPI 1154504082 CMS profile 52570

460 Northside Cherokee Blvd Ste 100, Canton, GA 30115

Open in the dashboard

General payments

$4,411

38 records reported · program years 2019–2025

Research payments

$12,360

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Kang of Canton, GA is reported in the CMS Open Payments database as having received $4,411 across 38 general payments and $12,360 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,046 7
2024 General $115 3
2023 General $354 9
2022 General $205 3
2021 General $125 4
2020 General $21 1
2020 Research $12,360 5
2019 General $545 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Kang
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Edward Kang were reported at $3,046. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Edward Kang Vascular Surgery median Middle half National median
2019 $545 $796 $226–$2,363 $163
2020 $21 $348 $118–$1,110 $114
2021 $125 $471 $158–$1,421 $132
2022 $205 $725 $222–$2,183 $149
2023 $354 $836 $257–$2,440 $160
2024 $115 $909 $252–$2,619 $164
2025 $3,046 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endologix, Inc. $3,018 6 payments
  2. Philips Electronics North America Corporation $256 5 payments
  3. Bard Peripheral Vascular, Inc. $226 5 payments
  4. AngioDynamics, Inc. $226 4 payments
  5. Avinger Inc. $173 2 payments
  6. Shockwave Medical, Inc $95 2 payments
  7. W. L. Gore & Associates, Inc. $81 1 payment
  8. Medtronic Vascular, Inc. $67 1 payment
  9. Medtronic, Inc. $43 1 payment
  10. Janssen Pharmaceuticals, Inc $37 2 payments
  11. Other $189 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,018 6 payments
  2. Food and Beverage $1,393 32 payments
Products named General payments · program years 2019–2025
  1. ENDOCROSS Device $3,018 6 payments
  2. Torus Stent Graft System $3,018 6 payments
  3. AURYON LASER SYSTEM 100-120 VAC $226 4 payments
  4. PANTHERIS $173 2 payments
  5. Trilogy 100 $130 2 payments
  6. IGT Devices Und $125 3 payments
  7. GORE VIABAHN VBX Balloon Expandable Endo $81 1 payment
  8. Endurant $67 1 payment
  9. Vascular Lithotripsy $65 1 payment
  10. Crosser iQ $48 2 payments
  11. Other $396 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Philips Electronics North America Corporation $12,360 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

308

Median for Vascular Surgery: 122

Drug cost

$109,684

Median for Vascular Surgery: $14,135

Branded share of claims

48.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 64 $74,652
Xarelto Rivaroxaban Brand 21 $23,306
Brilinta Ticagrelor Brand 16 $8,897
Rosuvastatin Calcium Generic 58 $982
Cilostazol Generic 20 $692
Clopidogrel Clopidogrel Bisulfate Brand 49 $598
Atorvastatin Calcium Generic 57 $525
Tramadol Hcl Generic 23 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$191,626

Medicare's payments for the services billed

Medicare patients

781

Average age 75

Services billed

1,746

381 women, 400 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 50%
Chronic kidney disease 36%
Diabetes 33%
Heart failure 29%
Atrial fibrillation 28%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record